Low-Dose Propranolol Prevents Functional Decline in Catecholamine-Induced Acute Heart Failure in Rats

Overview

Journal Toxics

Date 2022 May 27

PMID 35622651

Authors

Cheng-Ken Tsai

Bo-Hau Chen

Hsin-Hung Chen

Rebecca Jen-Ling Hsieh

Jui-Chen Lee

Yi-Ting Chu

Wen-Hsien Lu

Affiliations

Soon will be listed here.

Abstract

Severe hyper-catecholaminergic states likely cause heart failure and cardiac fibrosis. While previous studies demonstrated the effects of beta-blockade in experimental models of single-catecholamine excess states, the detailed benefits of beta-blockade in more realistic models of hyper-adrenergic states are less clearly understood. In this study, we examined different therapeutic dosages and the effects of propranolol in rats with hyper-acute catecholamine-induced heart failure, and subsequent cardiopulmonary changes. Rats (n = 41) underwent a 6 h infusion of epinephrine and norepinephrine alone, with additional low-dose (1 mg/kg) or high-dose propranolol (10 mg/kg) at hour 1. Cardiac and pulmonary tissues were examined after 6 h. Catecholamine-only groups had the lowest survival rate. Higher doses of propranolol (15 mg/kg) caused similarly low survival rates and were not further analyzed. All low-dose propranolol rats survived, with a modest survival improvement in the high-dose propranolol groups. Left ventricular (LV) systolic pressure and LV end-diastolic pressure improved maximally with low-dose propranolol. Cardiac immunohistochemistry revealed an LV upregulation of FGF-23 in the catecholamine groups, and this improved in low-dose propranolol groups. These results suggest catecholamine-induced heart failure initiates early pre-fibrotic pathways through FGF-23 upregulation. Low-dose propranolol exerted cardio-preventative effects through FGF-23 downregulation and hemodynamic-parameter improvement in our model of hyper-acute catecholamine-induced heart failure.

Citing Articles

Chinese and western medicine treatment of myocardial fibrosis drugs.

Zhu Y, Zhang F, Li Z, Zhou Y, Shu Y, Ruan J Front Cardiovasc Med. 2025; 11:1477601.

PMID: 39882321 PMC: 11774883. DOI: 10.3389/fcvm.2024.1477601.

Potential cardioprotective effect of paroxetine against ventricular remodeling in an animal model of myocardial infarction: a comparative study.

Alonazi A, Almodawah S, Aldigi R, Bin Dayel A, Alamin M, Almotairi A BMC Pharmacol Toxicol. 2024; 25(1):99.

PMID: 39696491 PMC: 11657438. DOI: 10.1186/s40360-024-00824-9.

Real-world research on beta-blocker usage trends in China and safety exploration based on the FDA Adverse Event Reporting System (FAERS).

Yan Y, An W, Mei S, Zhu Q, Li C, Yang L BMC Pharmacol Toxicol. 2024; 25(1):86.

PMID: 39543745 PMC: 11566443. DOI: 10.1186/s40360-024-00815-w.

The protective role of ginsenoside Rg3 in heart diseases and mental disorders.

Shi L, Luo J, Wei X, Xu X, Tu L Front Pharmacol. 2024; 15:1327033.

PMID: 38469409 PMC: 10926849. DOI: 10.3389/fphar.2024.1327033.

Drugs for treating myocardial fibrosis.

Ren Z, Zhang Z, Ling L, Liu X, Wang X Front Pharmacol. 2023; 14:1221881.

PMID: 37771726 PMC: 10523299. DOI: 10.3389/fphar.2023.1221881.

References

Downing S, Chen V . Myocardial injury following endogenous catecholamine release in rabbits. J Mol Cell Cardiol. 1985; 17(4):377-87. DOI: 10.1016/s0022-2828(85)80137-1. View

Dunser M, Hasibeder W . Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress. J Intensive Care Med. 2009; 24(5):293-316. DOI: 10.1177/0885066609340519. View

Jeschke U, Walzel H, Mylonas I, Papadopoulos P, Shabani N, Kuhn C . The human endometrium expresses the glycoprotein mucin-1 and shows positive correlation for Thomsen-Friedenreich epitope expression and galectin-1 binding. J Histochem Cytochem. 2009; 57(9):871-81. PMC: 2728131. DOI: 10.1369/jhc.2009.952085. View

Ferreira J, Bissell B . Misdirected Sympathy: The Role of Sympatholysis in Sepsis and Septic Shock. J Intensive Care Med. 2017; 33(2):74-86. DOI: 10.1177/0885066616689548. View

Macala K, Khadaroo R, Panahi S, Gragasin F, Bourque S . Low dose Intralipid resuscitation improves survival compared to ClinOleic in propranolol overdose in rats. PLoS One. 2018; 13(8):e0202871. PMC: 6116996. DOI: 10.1371/journal.pone.0202871. View

Rodriguez-Sinovas A, Sanchez J, Valls-Lacalle L, Consegal M, Ferreira-Gonzalez I . Connexins in the Heart: Regulation, Function and Involvement in Cardiac Disease. Int J Mol Sci. 2021; 22(9). PMC: 8122935. DOI: 10.3390/ijms22094413. View

Elenkov I, Wilder R, Chrousos G, Vizi E . The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000; 52(4):595-638. View

Lee Y, Seth M, Soney D, Dai H . Benefits of Beta-Blockade in Sepsis and Septic Shock: A Systematic Review. Clin Drug Investig. 2019; 39(5):429-440. DOI: 10.1007/s40261-019-00762-z. View

Macala K, Tabrizchi R . The effect of fat emulsion on hemodynamics following treatment with propranolol and clonidine in anesthetized rats. Acad Emerg Med. 2014; 21(11):1220-5. DOI: 10.1111/acem.12511. View

10.

Muders F, Friedrich E, Luchner A, Pfeifer M, Ickenstein G, Hamelbeck B . Hemodynamic changes and neurohumoral regulation during development of congestive heart failure in a model of epinephrine-induced cardiomyopathy in conscious rabbits. J Card Fail. 1999; 5(2):109-16. DOI: 10.1016/s1071-9164(99)90033-7. View

11.

Barth W, Deten A, Bauer M, Reinohs M, Leicht M, Zimmer H . Differential remodeling of the left and right heart after norepinephrine treatment in rats: studies on cytokines and collagen. J Mol Cell Cardiol. 2000; 32(2):273-84. DOI: 10.1006/jmcc.1999.1075. View

12.

Kanwar M, Irvin C, Frank J, Weber K, Rosman H . Confusion about epinephrine dosing leading to iatrogenic overdose: a life-threatening problem with a potential solution. Ann Emerg Med. 2009; 55(4):341-4. DOI: 10.1016/j.annemergmed.2009.11.008. View

13.

Nies A, SHAND D . Clinical pharmacology of propranolol. Circulation. 1975; 52(1):6-15. DOI: 10.1161/01.cir.52.1.6. View

14.

Tarvasmaki T, Lassus J, Varpula M, Sionis A, Sund R, Kober L . Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality. Crit Care. 2016; 20(1):208. PMC: 4931696. DOI: 10.1186/s13054-016-1387-1. View

15.

Hao H, Li X, Li Q, Lin H, Chen Z, Xie J . FGF23 promotes myocardial fibrosis in mice through activation of β-catenin. Oncotarget. 2016; 7(40):64649-64664. PMC: 5323105. DOI: 10.18632/oncotarget.11623. View

16.

Izumi Y, Okatani H, Shiota M, Nakao T, Ise R, Kito G . Effects of metoprolol on epinephrine-induced takotsubo-like left ventricular dysfunction in non-human primates. Hypertens Res. 2009; 32(5):339-46. DOI: 10.1038/hr.2009.28. View

17.

Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S . Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013; 310(16):1683-91. DOI: 10.1001/jama.2013.278477. View

18.

Briest W, Holzl A, Rassler B, Deten A, Leicht M, Baba H . Cardiac remodeling after long term norepinephrine treatment in rats. Cardiovasc Res. 2001; 52(2):265-73. DOI: 10.1016/s0008-6363(01)00398-4. View

19.

Leifheit-Nestler M, Kirchhoff F, Nespor J, Richter B, Soetje B, Klintschar M . Fibroblast growth factor 23 is induced by an activated renin-angiotensin-aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts. Nephrol Dial Transplant. 2018; 33(10):1722-1734. DOI: 10.1093/ndt/gfy006. View

20.

Floras J . Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol. 2009; 54(5):375-85. DOI: 10.1016/j.jacc.2009.03.061. View